4 completed, 1 terminated. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Terminated 1 |
Follow Point Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Talabostat and Cisplatin in Advanced Melanoma talabostat (PT-100) tablets, cisplatin - Melanoma, Skin Cancer | Phase 2 | Completed | Point Therapeutics | 2007-06-08 | ||
| Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL) Talabostat mesylate (PT-100) tablets, Rituximab - Chronic Lymphocytic Leukemia | Phase 2 | Completed | Point Therapeutics | 2015-03-25 | ||
| Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer talabostat (PT-100) tablets, Docetaxel - Lung Cancer | Phase 2 | Completed | Point Therapeutics | 2007-06-08 | ||
| Study of Talabostat in Advanced Melanoma talabostat (PT-100) tablets - Melanoma, Skin Cancer | Phase 2 | Completed | Point Therapeutics | 2007-06-08 | ||
| Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas talabostat mesylate tablets, gemcitabine - Pancreatic Cancer, Neoplasm Metastasis | Phase 2 | Terminated | Point Therapeutics | 60 | 2007-06-08 |
Melanoma (2) · Skin Neoplasms (2) · Adenocarcinoma (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1)
Tablets (4) · talabostat (4) · PT-100 dipeptide (2) · Cisplatin (1) · Docetaxel (1) · Gemcitabine (1) · Rituximab (1)
United States (5)